Granted Patent B2

US 12,697,371 · App. 17/420,974 · Granted Aug 4, 2026

Inventor: Mingdong Zhou (New South Wales, AU)

Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.

A61K38/1883

Abstract

Claims (8)

1 . A method for treating, or relieving myocardial injury in a mammal, comprising administering to the mammal an effective amount of neuregulin (NRG) at a dose of 2.5 μg/kg/day to 50 μg/kg/day multiple times a day for consecutive days, and following the administration slowly withdrawing the NRG through daily dose reduction within three weeks, wherein the daily dose is half of the administered dose in the first week; the daily dose is a quarter of the administered dose in the second week; and the daily dose is one eighth of the administered dose in the third week.

2 . The method according to claim 1 , wherein the NRG is NRG-1, NRG-2, NRG-3 or NRG-4.

3 . The method according to claim 1 , wherein the NRG is NRG-1.

4 . The method according to claim 1 , wherein the mammal is human.

5 . A method for treating, or relieving myocardial injury in a mammal, comprising administering to the mammal neuregulin (NRG) at a dose of 2.5 μg/kg/day to 50 μg/kg/day multiple times a day for consecutive days, and following the administration slowly withdrawing the NRG through frequency reduction within three weeks comprising: administering the NRG every other day in the first week; administering the NRG every three days in the second week; and administering the NRG every four days in the third week.

6 . The method according to claim 5 , wherein the NRG is NRG-1, NRG-2, NRG-3 or NRG-4.

7 . The method according to claim 5 , wherein the NRG is NRG-1.

8 . The method according to claim 5 , wherein the mammal is human.

Assignments (1)

Priority Claims (2)

Continuity (1)

References Cited (26)